Navigation Links
Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
Date:9/2/2010

related cutaneous/application site adverse events was slightly lower with TDLP-110 (1.1% vs. placebo 2.2%, respectively). There were no clinically relevant shifts from baseline in laboratory parameters (hematology, coagulation, serum chemistry, and urinalysis). The estimated systemic absorption of TDLP-110 is about 1 - 2 % of a comparable oral ketoprofen dose. In a pharmacokinetic sub-study of this Phase 3 trial minimal blood concentrations (mean Cmax 39.0 ng/mL) of ketoprofen were measured at steady-state, which is consistent with previous Phase 1/2 study findings. This Phase 3 study (TDLP-110-001) demonstrated that TDLP-110 was more effective than placebo in reducing pain of acute soft tissue injuries and was very well tolerated.

"Today's presentation of our data at the world's premier congress devoted to research and treatment of pain is a significant event for our company," stated Joachim Schupp, M.D., Chief Medical Officer at Transdel Pharmaceuticals. "We believe that study TDLP-110-001 could serve as one of two required confirmatory trials of evidence of efficacy for TDLP-110 and we plan to initiate the second trial upon sufficient funding."

To view the poster presented at the conference, please visit the Company's website at www.transdelpharma.com.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel™ cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier.  Ketotransdel®, the Company's lead pain product candidate, has completed a Phase 3 clinical trial and utilizes the Transdel™ technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlyi
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Transdel Pharmaceuticals Announces Management Reorganization
2. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
3. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
4. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
5. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
6. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
8. Pfizer to Acquire FoldRx Pharmaceuticals
9. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
10. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
11. Webcast Alert: Isis Pharmaceuticals Hosts Expert Panel Conference Call to Discuss Mipomersen Data Presented at the ESC Congress 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... July 12 MedPro Imaging, a leading supplier ... been chosen by the Chicago Bears Football Club, Inc. to ... other health issues for the team during the upcoming 2010 ... Mobile Imaging Services division which offers mobile ultrasound services throughout ...
... July 12 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... offer by its wholly owned subsidiary, HT Acquisition Corp., for all ... HTRN).  American Stock Transfer & Trust Company, the depositary for the ... , New York City time, on July 9, ...
Cached Medicine Technology:MedPro Imaging to Supply Mobile Ultrasound Diagnostics to Chicago Bears Players 2MedPro Imaging to Supply Mobile Ultrasound Diagnostics to Chicago Bears Players 3Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. 2Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. 3Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. 4
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:New MRSA superbug emerges in Brazil 2
... Presbyterian Medical Center, high rates of chronic hepatitis B infection ... the New York City area, and most of them do ... considered the standard of care for all persons newly identified ... but one infant was protected from infection in this study, ...
... whose mothers are successfully treated for depression show progressive and ... their moms discontinue treatment, new UT Southwestern Medical Center-led research ... their kids improved and the greater the degree of ... is depressed and don,t even go through the process of ...
... Reporter , MONDAY, May 9 (HealthDay News) -- Among Medicare ... new study finds. But at the same time, a ... may not always be getting the follow-up colonoscopies they need ... which blood is detected in the stool. Both reports ...
... Steven Reinberg HealthDay Reporter , MONDAY, May 9 ... with a lethal nervous system disease known as amyotrophic lateral ... however, that this does not mean people with long ring ... are at higher risk for it. "We have not ...
... By Maureen Salamon HealthDay Reporter , MONDAY, ... concerns, new Korean research suggests that long-term use of ... is linked to an increased risk of fractures. ... 1997 and 2011 found that proton pump inhibitors (PPIs), ...
... , MONDAY, May 9 (HealthDay News) -- People with ... of suffering another attack or dying after even a ... painkillers, including Advil, Motrin or Voltarin, a large ... of almost 84,000 heart attack survivors and found that ...
Cached Medicine News:Health News:Routine antenatal screening for hepatitis B in an urban NYC population 2Health News:Successful depression treatment of mothers has long-term effects on offspring 2Health News:Successful depression treatment of mothers has long-term effects on offspring 3Health News:Study Questions Overuse of Colonoscopy in Medicare Patients 2Health News:Study Questions Overuse of Colonoscopy in Medicare Patients 3Health News:Study Questions Overuse of Colonoscopy in Medicare Patients 4Health News:Ring Finger Length Linked to ALS, Study Suggests 2Health News:Ring Finger Length Linked to ALS, Study Suggests 3Health News:Popular Heartburn Meds May Boost Fracture Risk 2Health News:Popular Heartburn Meds May Boost Fracture Risk 3Health News:After Heart Attack, Certain Painkillers May Raise Risk for Recurrence 2Health News:After Heart Attack, Certain Painkillers May Raise Risk for Recurrence 3
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Medicine Products: